Biomarkers · Chemical
Glucose
A blood glucose test measures the glucose levels in your blood. Glucose is a type of sugar.
Blood Glucose Test, MedlinePlus, National Library of Medicine
The test measures the level of glucose, a type of sugar, in the blood. Insulin is the hormone that helps move glucose from the bloodstream into cells, where the body uses it for energy.
- Also listed as
- serum glucose, fasting glucose, blood glucose, blood sugar, plasma glucose, Glucose, Two-Hour Postprandial
- Primary unit
- mg/dL
- LOINC codes
- 1504-0, 1521-4, 1514-9, 1518-0, 1507-3, 12638-3, 2345-7
- Tests that measure Glucose
- Quest Diagnostics 30, Labcorp 23
See why clinicians order the test
Clinicians most commonly order glucose testing to screen for and monitor prediabetes and diabetes.
Condition: Prediabetes
Clinicians order the test to help find the cause of symptoms that suggest blood glucose is too high or too low.
Goal: Blood sugar
Clinicians use the test to monitor side effects of certain medicines taken over the long term that can affect blood glucose.
Clinicians commonly order glucose testing between the 24th and 28th week of pregnancy to check for gestational diabetes.
Raised fasting glucose is one of the recognized risk factors clinicians use when assessing for metabolic syndrome.
Condition: Metabolic syndrome
Read with companion markers
Clinicians read fasting glucose with HDL cholesterol because raised glucose and lowered HDL both count among metabolic syndrome risk factors.
Clinicians read fasting glucose with triglycerides because raised levels of both count among the clustered risk factors of metabolic syndrome.
Clinicians often confirm a raised HbA1c with a repeat HbA1c or another diabetes test, usually fasting blood glucose or an oral glucose tolerance test.
Choose the right version
Hemoglobin A1cAlternative test
The HbA1c test gives information about average blood glucose levels across the past 3 months from a single blood sample.
Check what can shift results
Prepare for the test
Each statement links to the source we wrote it from. Last updated October 19, 2026.
Ranges
Compare the reference ranges labs publish with guideline targets, diagnostic cut-offs, study-based ranges and practitioner targets. Move across the rows to check a value against each range, and open a source from the legend. How to read these ranges
All 5 published ranges, with sources
Lab reference ranges
Diagnostic cut-offs
ADA diabetes threshold, fasting126 mg/dL and above
Nonpregnant adults, fasting
126 mg/dL (7.0 mmol/L) or higher.
ADA impaired fasting glucose100 to 125 mg/dL
Nonpregnant adults, fasting
100 to 125 mg/dL (5.6 to 6.9 mmol/L).
Metabolic syndrome criterion100 mg/dL and above
Adults, fasting
Fasting glucose of 100 mg/dL or higher counts as one of five criteria.
Tests
Check the catalog code, specimen, method and preparation for every test that measures Glucose. Select up to five tests to compare them side by side.
Quest Diagnostics 30 tests
Single-analyte tests
Cardio IQ® Glucose 91947
Serum · Fasting required · Turnaround Set up: Tues-Sat
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Preparation
- Fasting required. Fasting is defined as no consumption of food or beverage other than water for at least 8 hours prior to collection.
- Collection
- Serum submissions must be separated from cells
- Reference notes
- 65-99 mg/dL
Glucose 483
Serum · Fasting not stated · Turnaround Set up: Mon-Sat; Report available: 3 days
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Preparation
- Fasting preferred. Fasting is defined as no consumption of food or beverage other than water for at least 8 hours before testing.
- Collection
- Serum and plasma submissions must be separated from cells
- Reference notes
- Fasting Reference Interval | 65-99 mg/dL Non-fasting Reference Interval | 65-139 mg/dL
Glucose Tolerance Test, Postprandial/2-Hour 4637
Plasma · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Collection
- Specimen is obtained 2 hours following a meal. Serum and plasma submissions must be separated from cells.
- Reference notes
- <140 mg/dL
Glucose, Gestational Screen (50g), 135 Cutoff 8477
Plasma · No fasting · Turnaround Set up: Daily (Day shift); Report available: 3 days
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Preparation
- Fasting is not required
- Collection
- The patient is given a 50 g dose of glucose and a single blood specimen is obtained one hour later. Serum and plasma submissions must be separated from cells. Note: The test should be performed between weeks 24 and 28 of gestation.
- Reference notes
- <135 mg/dL
Glucose, Gestational Screen (50g), 140 Cutoff 19833
Plasma · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Collection
- The test should be performed between weeks 24 and 28 of gestation. The patient is given a 50 g dose of glucose and a single blood specimen is obtained one hour later. Fasting is not required. Note: Serum and plasma submissions must be separated from cells.
- Reference notes
- <140 mg/dL
Glucose, Random 8917
Serum · Fasting not stated · Turnaround Set up: Mon-Sat; Report available: 3 days
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP)
- Collection
- Note: Serum and plasma submissions must be separated from cells
- Reference notes
- <140 mg/dL
Panels that include this biomarker
Diabetes and ASCVD Risk Panel with Scores 92062
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Collection
- For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female) Race - African American: Y (for yes) or N (for no) Systolic Blood Pressure: mmHg Treatment for High B.P.: Y (for yes) or N (for no) Diabetes Status: Y (for yes) or N (for no) Smoking Status: Y (for yes) or N (for no)
- Reference notes
- See individual tests
Diabetes Risk Panel with Score 92027
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Turbidimetric Inhibition Immunoassay • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Collection
- For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female)
- Reference notes
- See individual tests
Metabolic Syndrome and Glucose Control Including Insulin 91398
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Chromatography/Mass Spectrometry • Spectrophotometry (SP)
- Preparation
- If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required. The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
- Reference notes
- See Laboratory Report
NAFLD Fibrosis Score 91979
7 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Spectrophotometry (SP) • Electronic Sizing and Counting/Cytometry/Microscopy
- Preparation
- Fasting preferred. Fasting is defined as no consumption of food or beverage other than water for at least 8 hours before testing.
- Collection
- For risk calculations to be performed, the following patient-specific information must be provided at the time of order: Age: Years Gender: M (for male) or F (for female) Height Feet: Feet Height Inches: Inches Weight: lbs. Diabetes Status: Y (for yes) or N (for no)
- Reference notes
- See Laboratory Report
Basic Metabolic Panel without Calcium 34388
8 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- See individual tests
- Preparation
- Fasting specimen is preferred
- Reference notes
- See Laboratory Report
Labcorp 23 tests
Single-analyte tests
Gestational Diabetes Screen (ACOG Recommendations) 102277
Serum · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- None; glucose challenge is administered without regard to time of day or time of last meal.
- Collection
- Note: A fasting blood sample is not required. Draw one hour specimen after a 50-gram glucose challenge. The patient should remain seated and not smoke throughout the test. Submit 1 mL serum or plasma for one-hour specimen. Separate serum or plasma from cells within 45 minutes of venipuncture. Gray-top tubes only, may be submitted without centrifugation. Label tube with patient's name and collection time interval (i.e., one-hour).
- Reference notes
- 70−139 mg/dL
Glucose 001032
Serum · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Blood should be drawn in the morning after an overnight fast. Per the American Diabetes Association (ADA), fasting is defined as no caloric intake for at least eight hours.1
- Collection
- Separate serum or plasma from cells within 45 minutes of collection. Label specimen as serum or lithium heparin plasma.
- Reference notes
- 70−99 mg/dL
Glucose, Two-hour Postprandial 002022
Serum · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Adequate meal or 75-gram glucose load two hours before two-hour postprandial glucose, as specified by the patient's physician. Patient is allowed usual meal (breakfast or lunch). Patient must complete meal within 15 to 20 minutes.
- Collection
- Collect specimen two hours from the beginning of meal. Separate serum or plasma from cells within 45 minutes of venipuncture. Gray-top tubes only, may be submitted without centrifugation. Label tube with patient's name and collection time.
- Reference notes
- 65−139 mg/dL
Panels that include this biomarker
Gestational Glucose Tolerance Screening and Diagnostic Test (Two-hour, ADA Recommendations) 101000
2 analytes · Serum · Fasting not stated · Turnaround Within1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Patient should be active and eat a regular diet that includes at least 150 grams of carbohydrate daily for three days prior to the test. The patient should be instructed not to eat or drink anything except water for at least eight hours and not more than 14 hours before the test. Patients should also be advised to discontinue, whenever possible, all nonessential medication that can affect glucose metabolism at least three days before testing.
- Collection
- Draw a fasting blood sample before administering glucose. Administer a 75-gram glucose and draw blood after one hour and two hours. The patient should remain seated throughout the test. Submit 1 mL serum or plasma for fasting, one-hour, and two-hour specimens. Separate serum or plasma from cells within 45 minutes of venipuncture. Gray-top tubes only, may be submitted without centrifugation. Label each tube with the patient's name and collection time interval (i.e,, fasting, one-hour, and two-hour).
- Reference notes
- See table. Specimen (Two-hour GGT Test)* Range (mg/dL) *A positive diagnosis requires that only one of the high thresholds be exceeded. Fasting 70−91 One-hour 70−179 Two-hour 70−152
Glucose Tolerance Test (GTT), Two-hour (Oral WHO Protocol) 101200
2 analytes · Serum · Fasting not stated · Turnaround Within1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Patient should be active and eat a regular diet that includes at least 150 grams of carbohydrate daily for three days prior to the test. Patient should be instructed not to eat or drink anything except water for at least eight hours and not more than 14 hours before the test. Patients should also be advised to discontinue, whenever possible, all nonessential medication that can affect glucose metabolism at least three days before testing.
- Collection
- Draw a fasting blood sample before administering glucose. Administer a 75-gram glucose and draw blood after two hours. The patient should remain seated throughout the test. Submit 1 mL serum or plasma for fasting and two-hour specimens. Separate serum or plasma from cells within 45 minutes of venipuncture. Gray-top tubes only, may be submitted without centrifugation. Label each tube with the patient's name and collection time interval. (ie, fasting and two-hour).
Metabolic Syndrome Profile 335884
3 analytes · Serum · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Patient should be fasting for 12 to 14 hours and on a stable diet for two weeks prior to blood collection.
- Collection
- Separate serum or plasma from cells within 45 minutes of collection. Label gray-top tube as plasma.
Gestational Glucose Tolerance Diagnostic Test (Three-hour, ACOG Recommendations) 102004
4 analytes · Serum · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- For three days prior to the test, patients should eat an unrestricted diet of 150 or more grams of carbohydrate and be permitted unrestricted physical activity. Patients should be instructed to eat and drink nothing except water for at least eight hours and not more than 14 hours before the test. Patients should also be advised to discontinue, whenever possible, all nonessential medication that can affect glucose metabolism at least three days before testing.
- Collection
- Draw a fasting blood sugar before administering 100-gram glucose, and draw blood at one, two, and three hours. The subject should remain seated and not smoke throughout the test. Submit 1 mL serum or plasma for fasting, one-hour, two-hour, and three-hour specimens. Separate serum or plasma from cells within 45 minutes of venipuncture. Gray-top tubes only, may be submitted without centrifugation. Label each tube with patient's name and collection time interval (i.e., fasting, one-hour, two-hour, and three-hour).
- Reference notes
- See table. Specimen* Plasma or Serum Glucose Level (Carpenter and Coustan Conversion) Plasma Glucose Level (National Diabetes Data Group Conversion) *The diagnosis of GDM can be made based on the result of the 100-gram, three-hour oral glucose tolerance test, for which there is evidence that treatment improves outcome. Either the plasma or serum glucose level established by Carpenter and Coustan or the plasma level designated by the National Diabetes Data Group is appropriate to use. A positive diagnosis requires that two or more high thresholds be exceeded. The Carpenter and Coustan conversion is used to establish Labcorp reference intervals. Fasting 70−94 mg/dL 70−105 mg/dL One-hour 70−179 mg/dL 70−190 mg/dL Two-hour 70−154 mg/dL 70−165 mg/dL Three-hour 70−139 mg/dL 70−145 mg/dL
Lactose Tolerance Test 046300
5 analytes · Plasma · Fasting not stated · Turnaround Within 1 day
Labcorp catalog pageMethod and collection
- Method
- Enzymatic
- Preparation
- Patient should fast for eight hours before testing. No smoking or gum chewing allowed during test. Patient is encouraged to drink a moderate amount, one to two glasses of water during test. Patient should remain seated or in bed during test.
- Collection
- Draw fasting sample prior to lactose administration. Give lactose according to the following: • Children up to 12 years: 2 g/kg body weight with a maximum of 50 g in 250 mL water. • Adults: 50 g in 250 mL water Collect specimens at 30, 60, 90, and 120 minutes following lactose administration. Label each tube with the patient's name and time of drawing according to the following: The first tube should be labeled with the "patient's name," "fasting," and the time of the draw. The remaining four tubes should be labeled with the "patient's name" and the time of the draw.
0 of 5 tests selected
Pick one moreGoals and conditions
We link Glucose to these goals and conditions from named guidelines and studies.
Blood sugarGoal, primary marker
ADA diagnoses diabetes at a fasting glucose of 126 mg/dL or higher and impaired fasting glucose at 100 to 125 mg/dL.
Metabolic dysfunction-associated steatotic liver disease (MASLD)Condition, ICD-10 K76.0, companion marker
Fasting glucose of 100 mg/dL or higher is one of the MASLD cardiometabolic criteria.
Metabolic syndromeCondition, ICD-10 E88.810, primary marker
Fasting glucose of 100 mg/dL or higher is one of the five harmonized criteria.
PrediabetesCondition, ICD-10 R73.03, primary marker
ADA defines impaired fasting glucose as 100 to 125 mg/dL (5.6 to 6.9 mmol/L).
Type 2 diabetesCondition, ICD-10 E11.9, primary marker
ADA diagnoses diabetes at a fasting plasma glucose of 126 mg/dL (7.0 mmol/L) or higher.
Sources
Check the guidelines, studies and lab catalogs behind every range and link on this page. Open a source to see each claim it backs.
Clinical guidelines
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2026
American Diabetes Association, 2026
Diagnostic cut-off: ADA diabetes threshold, fasting, 126 mg/dL and above
Population: Nonpregnant adults, fasting
126 mg/dL (7.0 mmol/L) or higher.
Diagnostic cut-off: ADA impaired fasting glucose, 100 to 125 mg/dL
Population: Nonpregnant adults, fasting
100 to 125 mg/dL (5.6 to 6.9 mmol/L).
Linked to Blood sugar (primary)
ADA diagnoses diabetes at a fasting glucose of 126 mg/dL or higher and impaired fasting glucose at 100 to 125 mg/dL.
Linked to Prediabetes (primary)
ADA defines impaired fasting glucose as 100 to 125 mg/dL (5.6 to 6.9 mmol/L).
Linked to Type 2 diabetes (primary)
ADA diagnoses diabetes at a fasting plasma glucose of 126 mg/dL (7.0 mmol/L) or higher.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
AASLD, EASL and ALEH, 2023
Linked to Metabolic dysfunction-associated steatotic liver disease (MASLD) (companion)
Fasting glucose of 100 mg/dL or higher is one of the MASLD cardiometabolic criteria.
Harmonizing the Metabolic Syndrome: a joint interim statement of the IDF, NHLBI, AHA, World Heart Federation, International Atherosclerosis Society and International Association for the Study of Obesity
International Diabetes Federation, NHLBI, American Heart Association and partners, 2009
Read together with
Clinicians read fasting glucose with HDL cholesterol because raised glucose and lowered HDL both count among metabolic syndrome risk factors.
“The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity.”
Read together with
Clinicians read fasting glucose with triglycerides because raised levels of both count among the clustered risk factors of metabolic syndrome.
“The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity.”
Reasons to test
Raised fasting glucose is one of the recognized risk factors clinicians use when assessing for metabolic syndrome.
“The risk factors include raised blood pressure, dyslipidemia (raised triglycerides and lowered high-density lipoprotein cholesterol), raised fasting glucose, and central obesity.”
Diagnostic cut-off: Metabolic syndrome criterion, 100 mg/dL and above
Population: Adults, fasting
Fasting glucose of 100 mg/dL or higher counts as one of five criteria.
Linked to Metabolic syndrome (primary)
Fasting glucose of 100 mg/dL or higher is one of the five harmonized criteria.
Read together with
Fasting glucose is read with triglycerides because raised fasting glucose and raised triglycerides both count as metabolic syndrome risk factors.
Read together with
Clinicians read HDL alongside fasting glucose because lowered HDL and raised fasting glucose both count as metabolic syndrome risk factors.
Lab catalogs
Labcorp test menu, Glucose (001032)
2026
Lab reference range: Labcorp, adults, 70 to 99 mg/dL
Retrieved October 16, 2026
Quest Diagnostics Test Directory, Glucose (483)
2025
Lab reference range: Quest, fasting, 65 to 99 mg/dL
Population: Adults, fasting
Retrieved October 12, 2025
Labcorp test menu
Labcorp
Test catalog: 23 tests, with codes, specimens, methods and reference intervals
Quest Diagnostics test menu
Quest Diagnostics
Test catalog: 30 tests, with codes, specimens, methods and reference intervals
Reference sources
Blood Glucose Test
MedlinePlus, National Library of Medicine
Before the test
When glucose is measured as part of a BMP or CMP panel, fasting may be required.
“If your glucose test is part of a BMP or CMP test, you may need to fast.”
Before the test
A fasting blood glucose test or an oral glucose tolerance test requires fasting for at least eight hours beforehand.
“If your provider orders a fasting blood glucose test or an oral glucose tolerance test, you will need to fast for at least eight hours before the test.”
Reasons to test
Clinicians commonly order glucose testing between the 24th and 28th week of pregnancy to check for gestational diabetes.
“You will likely have a blood glucose test between the 24th and 28th week of your pregnancy to check for gestational diabetes.”
Reasons to test
Clinicians use the test to monitor side effects of certain medicines taken over the long term that can affect blood glucose.
“To monitor the side effects of certain long-term medicines that may affect blood glucose”
Reasons to test
Clinicians order the test to help find the cause of symptoms that suggest blood glucose is too high or too low.
“To help diagnose the cause of symptoms that may mean your blood glucose is too high or too low”
Reasons to test
Clinicians most commonly order glucose testing to screen for and monitor prediabetes and diabetes.
“The most common reasons for a blood glucose test are to screen for and monitor prediabetes and diabetes.”
Versions of the test
The HbA1c test gives information about average blood glucose levels across the past 3 months from a single blood sample.
“A hemoglobin A1C (HbA1c) test provides information about your average blood glucose levels over the past 3 months.”
What can shift results
Certain types of medicines can cause high blood glucose in some people who take them.
“Examples of medicines that may cause high blood glucose in some people include certain types of:”
What can shift results
Problems with the pancreas or adrenal glands can raise blood glucose apart from diabetes, as can side effects of certain medicines.
“High blood glucose may also be caused by other conditions that can affect insulin or glucose levels in your blood, such as problems with your pancreas or adrenal glands, and side effects from certain medicines.”
What it reflects
Insulin is the hormone that helps move glucose from the bloodstream into cells, where the body uses it for energy.
“A hormone called insulin helps move glucose from your bloodstream into your cells for use as energy.”
What it reflects
The test measures the level of glucose, a type of sugar, in the blood.
“A blood glucose test measures the glucose levels in your blood.”
Retrieved October 19, 2026
Hemoglobin A1C (HbA1c) Test
MedlinePlus, National Library of Medicine
Read together with
Clinicians often confirm a raised HbA1c with a repeat HbA1c or another diabetes test, usually fasting blood glucose or an oral glucose tolerance test.
Retrieved October 19, 2026
Blood Glucose Test
MedlinePlus, National Library of Medicine
The description at the top of this page
Codes and registries
Verify these ranges and sources
We compile this page from named laboratory catalogs, guidelines and studies. Labs calculate reference intervals from the people they test, for one assay method and one population group, so an interval describes that population rather than an optimal target.
Interpret your own results with a licensed clinician, or track your lab history and health goals in Aumnivida.
Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.